FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
63 letters match. Newest first.
-
BiologicsValley Biosystems
FDA cited Valley Biosystems, a California biologics testing lab, for Good Laboratory Practice violations that call its nonclinical study data into question.
High risk -
BiologicsVitti Labs, LLC
FDA warns Vitti Labs over unapproved umbilical cord and amniotic membrane products and sterile manufacturing failures.
High risk -
BiologicsRe-Gen Active Lab, Inc.
FDA warned Re-Gen Active Lab over unapproved amniotic/umbilical cord injectables and serious sterility failures.
High risk -
BiologicsToxikon Corporation/Labcorp Bedford LLC
FDA warned Toxikon/Labcorp Bedford over GLP violations in a biologics nonclinical study, including incorrect kidney-function calculations and failed QA review.
Medium -
BiologicsSmart Surgical, Inc dba Burst Biologics
Burst Biologics distributed unapproved umbilical cord blood products as drugs while failing sterility and donor-screening rules.
High risk -
DrugsVasyl Melnyk, M.D.
FDA warns Dr. Vasyl Melnyk that he lost required records for an investigational drug trial.
Medium -
BiologicsSurgenex LLC
FDA warned Surgenex it sold unapproved umbilical cord and amniotic membrane products for injection without a biologics license and with serious manufacturing problems.
High risk -
DrugsEmpower Clinic Services, LLC dba Empower Pharmacy
FDA warns Empower Pharmacy its compounded drugs missed outsourcing-facility conditions, including labeling and adverse-event reporting.
Medium -
BiologicsUtah Cord Bank LLC dba Utah Cell Bank
Utah Cell Bank made unapproved injectable stem cell products and fell short on sterility and manufacturing controls, FDA found.
High risk -
DrugsBlue Willow Biologics
FDA warned Blue Willow Biologics over its NanoBio Protect nasal antiseptic sold with unapproved COVID-19 prevention and treatment claims.
High risk -
BiologicsDavati Medical Supply LLC
FDA warned Davati Medical Supply for selling unapproved, unlicensed FLUZALP Quadrivalent influenza vaccine online in the U.S.
High risk -
BiologicsUtah Cord Bank LLC
FDA cited Utah Cord Bank for unvalidated cord blood processing, missing environmental monitoring, procedures, and records after a February 2021 inspection.
High risk -
DrugsAllay Pharmaceuticals, LLC
FDA warned Allay Pharmaceuticals over CGMP failures and sub-potent tablets, and distribution of an unapproved biological product.
High risk